The Role of Imdur in Cortisol-Induced Hypertension in Humans
Not Applicable
Completed
- Conditions
- HypertensionCardiovascular - Hypertension
- Registration Number
- ACTRN12614000928617
- Lead Sponsor
- Dr John Kelly
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 8
Inclusion Criteria
Healthy male volunteers on no regular medications
Exclusion Criteria
Prior history of high blood pressure or diabetes.
History of allergy to oral compounds in the study protocol.
Any comorbid medical conditions that may be exacerbated by oral hydrocortisone e,g gastro-oesophageal reflux, anxienty, sleep disorder, mood disorder.
Requirment for any regular medication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain isosorbide mononitrate's antihypertensive effects in cortisol-induced hypertension?
How does isosorbide mononitrate compare to standard-of-care agents like ACE inhibitors in hydrocortisone-induced blood pressure elevation?
Which biomarkers predict response to isosorbide mononitrate in cortisol-induced hypertension models?
What adverse events are associated with isosorbide mononitrate and hydrocortisone co-administration in ACTRN12614000928617?
Are there alternative nitrates or combination therapies for cortisol-induced hypertension beyond isosorbide mononitrate?